Skip to main content
. 2019 Aug 29;10(4-6):161–167. doi: 10.1007/s12672-019-00367-0

Table 3.

First- and second-line therapies utilized in the treatment in patients with ACC

First line (N = 36) Second line (N = 23)
EDPM 21/36 8/23
Mitotane (single agent) 9/36 1/23
Gemcitabine and capecitabine 1/23
Cisplatin and etoposide (+/−mitotane) 2/23
Clinical trial 6/36 11/23

ACC, adrenal cortical carcinoma; EDPM, mitotane plus etoposide, doxorubicin, and cisplatin